RP1 Accelerated Approval: Regulatory Milestone Built on Surrogate Endpoint, Confirmatory Trial Is the Real Test

Specialized FDA Adcomm Leads to Accelerated Approval for Replimune's RP1

The article highlights the successful accelerated approval of Replimune's immunotherapy RP1 (now Tudriqev) for advanced melanoma, following a 10-3 positive vote from an FDA advisory committee. This outcome is presented as a prime example of the benefits of specialized expertise in regulatory reviews, where melanoma specialists on the committee corrected agency errors and acknowledged the unmet need, leading to a decision that was reasonably likely to predict clinically meaningful benefit. The author contrasts this with other rare disease reviews where a lack of specialized input led to different outcomes, advocating for broader FDA reforms.

• Replimune's RP1, an immunotherapy for advanced melanoma, secured accelerated approval after its FDA advisory committee voted 10-3 in favor. The committee, comprising melanoma specialists from institutions like MD Anderson and Memorial Sloan Kettering, played a crucial role by correcting agency errors and recognizing the significant unmet need, demonstrating the impact of disease-specific expertise.
• The positive adcomm vote for RP1, which concluded that the results were reasonably likely to predict clinically meaningful benefit, directly led to its accelerated approval as Tudriqev. This swift regulatory success is presented as a model for how the FDA should conduct reviews, particularly for novel therapies addressing serious conditions, by leveraging deep clinical and research experience.
• The author uses the Replimune case to advocate for broader structural reforms within the FDA. These reforms include establishing centers of excellence organized by practice groups and ensuring advisory committees are populated by clinicians with true sub-specialization. This approach aims to ensure consistent, expert-driven decision-making across all therapeutic areas, especially for rare diseases.

Tudriqev's IGNYTE Trial: Key Safety and Efficacy Outcomes

Recent clinical investigations into advanced melanoma have evaluated a range of interventions — from LAG-3 inhibition to combination checkpoint blockade and targeted BRAF/MEK inhibition — across diverse patient populations. The studies below highlight key safety and efficacy findings from this body of evidence.

• Safety and Efficacy of Anti-LAG-3 for Patients with Melanoma (Systematic Review and Meta-analysis, 2025): This meta-analysis evaluated anti-LAG-3 antibodies (including relatlimab) in combination regimens for melanoma. Pooled efficacy data demonstrated encouraging outcomes across progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). On the safety side, any-grade treatment-related adverse events (trAEs) occurred in 66% of patients (95% CI: 51%–81%), with grade ≥3 trAEs in 19% (95% CI: 11%–27%). Any-grade AEs leading to discontinuation were reported in 12% (95% CI: 9%–14%), and grade ≥3 AEs leading to discontinuation in 8% (95% CI: 6%–10%). The most common AEs included fatigue, pneumonitis, rash, pruritus, colitis, hepatitis, diarrhea, hypothyroidism, thyroiditis, and adrenal insufficiency.

• KEYNOTE-029 Part 1B (2021): This phase Ib expansion cohort assessed standard-dose pembrolizumab (2 mg/kg, amended to 200 mg, every 3 weeks) plus reduced-dose ipilimumab (1 mg/kg every 3 weeks for four cycles) in patients with advanced melanoma and no prior immune checkpoint inhibitor therapy. At a median follow-up of 36.8 months, the ORR was 62.1%, comprising 27.5% complete responses and 34.6% partial responses. Median duration of response (DOR) was not reached, with a 36-month ongoing response rate of 84.2%. Median PFS and OS were also not reached; 36-month rates were 59.1% and 73.4%, respectively. Treatment-related adverse events occurred in 96.1% of patients (47.1% grade 3/4; no deaths), with discontinuation of one or both study drugs in 35.9%.

• ADOREG Registry Analysis — MAPKinase Inhibition After ICI Failure (2022): This multicenter prospective registry study evaluated second-line combined BRAF plus MEK inhibition in 108 patients with BRAF^V600-mutated advanced melanoma who had progressed on PD-1-based immunotherapy (nivolumab, pembrolizumab, or ipilimumab plus nivolumab). Median PFS on subsequent targeted therapy was 6.6 months (95% CI: 5.4–7.8), and median OS from start of second-line targeted therapy was 16.0 months (95% CI: 11.2–20.8). The ORR and disease control rate (DCR) to targeted therapy were 42.6% and 55.6%, respectively. Three-year PFS and OS rates on second-line targeted therapy were 16% and 30%.

• KEYNOTE-001, -002, -006 Post-hoc Analysis — Mucosal Melanoma (2019): This post-hoc analysis assessed pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks) in 84 patients with advanced mucosal melanoma. The ORR was 19% (95% CI: 11%–29%), with a median DOR of 27.6 months. Median PFS was 2.8 months (95% CI: 2.7–2.8) and median OS was 11.3 months (95% CI: 7.7–16.6). ORR was 22% (95% CI: 11%–35%) in ipilimumab-naive patients and 15% (95% CI: 5%–32%) in ipilimumab-treated patients.

Addressing Unmet Needs in Advanced Melanoma Treatment

Despite remarkable advances in targeted therapy and immunotherapy, the management of advanced melanoma remains constrained by several critical challenges — including resistance mechanisms, toxicity burdens, and heterogeneous patient responses — that limit the durability and breadth of clinical benefit.

• Acquired and primary resistance to BRAF/MEK inhibitors: Acquired resistance to MAPK inhibitor therapy develops in the majority of patients at approximately 12 months. Resistance mechanisms include reactivation of the MAPK pathway through secondary NRAS mutations, MEK1 mutations (including MEK1(Q56P) and MEK1(E203K)), BRAF alternative splicing, and activation of parallel signalling pathways such as the PI3K-mTOR pathway. Intra-tumor heterogeneity — specifically the presence of clones lacking BRAF mutations — further complicates targeted therapy, as wildtype BRAF can be activated by inhibitors designed to target mutated BRAF.

• Primary and acquired resistance to immune checkpoint blockade (ICB): Approximately 40% of patients experience primary resistance to ipilimumab plus nivolumab combination therapy, while around 50% experience secondary resistance. Resistance to ICB can occur at each stage of the tumor's immune response and is categorised into tumor-derived mechanisms, T cell-based mechanisms, and tumor microenvironment-determined resistance. Loss of MHC class I membrane expression — observed in 78 of 181 cases (43%) in one study — predicted primary resistance to anti-CTLA-4 therapy, while MHC class II expression on >1% of cells predicted response to anti-PD-1 therapy, underscoring the complexity of patient stratification.

• Immune-related adverse events (irAEs) with checkpoint inhibitors: While PD-1/PD-L1 inhibitors are overall better tolerated than chemotherapy, they carry an increased risk of immune-related adverse events including colitis, pneumonitis, hepatitis, endocrinopathies, aminotransferase elevations, hypothyroidism, and hyperthyroidism. IrAEs can occur in every organ, even simultaneously, and can manifest weeks or months after discontinuation of checkpoint inhibitors. Persistent irAEs and treatment-related deaths have been reported, primarily in patients treated with ipilimumab.

• Poor outcomes in high-risk patient subgroups: Elevated lactate dehydrogenase (LDH), ECOG performance status ≥1, ≥3 metastatic sites, and the presence of brain metastases are significantly associated with shorter progression-free survival in patients treated with dabrafenib plus trametinib. In patients treated with pembrolizumab, elevated LDH was associated with a significant reduction in PFS compared with normal LDH levels (5 months vs. not reached; P=0.02), confirming that high LDH persists as an independent prognostic biomarker of poor prognosis even in the immunotherapy era.

• Limited efficacy in advanced-line settings and specific melanoma subtypes: In real-world use of lenvatinib plus anti-PD-1 in the advanced-line setting, the overall response rate was 28% and the disease control rate was 38%, with a median progression-free survival of only 3 months and a median overall survival of 11 months. Grade 3–4 toxicity was observed in 31% of patients, requiring dose interruptions and reductions, highlighting the tolerability challenges of combination regimens in heavily pre-treated populations.

Tudriqev's Role in the Evolving Advanced Melanoma Landscape

The treatment landscape for advanced melanoma has undergone substantial transformation, driven by parallel advances in targeted therapy and immunotherapy. Three BRAF/MEK inhibitor combinations — dabrafenib plus trametinib, vemurafenib plus cobimetinib, and encorafenib plus binimetinib — are established as standard of care for BRAF V600-mutant disease. A network meta-analysis across the coBRIM, COMBI-v, and Columbus phase 3 trials (1,230 patients total) revealed no statistically significant differences in overall survival (OS), progression-free survival (PFS), or overall response rate (ORR) among the three combinations, though their safety profiles differ. In parallel, a matching-adjusted indirect comparison demonstrated that nivolumab plus ipilimumab conferred improved OS versus all three BRAF/MEK inhibitor doublets over the full study period (hazard ratios of 0.53, 0.60, and 0.50 versus dabrafenib plus trametinib, encorafenib plus binimetinib, and vemurafenib plus cobimetinib, respectively), with the most pronounced OS and PFS benefits emerging after 12 months of treatment initiation. Real-world data from the Netherlands Cancer Registry further corroborate the durability of immunotherapy, with a five-year OS of 43.8% observed in stage IV melanoma patients receiving first-line immune checkpoint inhibitors.

Beyond the established PD-1/CTLA-4 axis, the approval of relatlimab — a LAG-3 inhibitor — in combination with nivolumab has introduced a novel immunotherapy doublet for previously untreated metastatic or unresectable melanoma. This combination significantly improved PFS compared to anti-PD-1 monotherapy and offers a potentially more tolerable alternative to nivolumab plus ipilimumab, which is limited in routine practice to approximately half of patients due to high toxicity. A randomized phase 2 lead-in trial further characterized the immunological dynamics of this combination, finding that simultaneous blockade of LAG-3 and PD-1 pathways was superior to sequential monotherapy lead-ins, with major pathologic response on biopsy at week 4 serving as an early surrogate marker of response and long-term PFS. Additionally, the triplet of atezolizumab, vemurafenib, and cobimetinib received FDA approval for untreated BRAF-mutant metastatic melanoma, reflecting the clinical interest in combining immunotherapy with targeted agents based on preclinical signals of synergy.

Sequencing strategies and biomarker-driven patient selection have also gained clinical relevance. Second-line anti-PD-1 immunotherapy with nivolumab or pembrolizumab following BRAFi/MEKi failure demonstrated activity in BRAF-mutant melanoma, with the greatest clinical benefit observed in patients with lactate dehydrogenase at or below the upper limit of normal, fewer than three organ sites with metastasis, and time to progression exceeding six months on first-line targeted therapy. In the neoadjuvant setting, immune checkpoint blockade and targeted therapies — including dabrafenib plus trametinib — have shown promise for high-risk stage 3 patients, with pathologic complete response after neoadjuvant immune checkpoint blockade emerging as a reliable predictor of improved prognosis. Furthermore, analysis of HLA-DR alleles in patients receiving immune checkpoint inhibitors suggested that specific alleles are associated with distinct immune-related adverse events, and that the occurrence of such adverse events correlated with higher treatment response rates and increased survival, pointing toward a potential role for HLA genotyping in pre-treatment risk stratification.

Oncolytic Viruses Gain Ground in Advanced Melanoma

The recent accelerated approval of Replimune's RP1 (Tudriqev) for advanced melanoma marks a pivotal moment, signaling a new wave of therapeutic options for patients grappling with this aggressive cancer. Despite significant advancements in recent years, including the introduction of immune checkpoint inhibitors and BRAF/MEK inhibitors, a substantial unmet need persists for patients who experience resistance or disease progression. RP1, as an oncolytic virus, offers a unique mechanism of action, directly targeting tumor cells while also stimulating a systemic immune response. This approach builds upon the foundation laid by earlier oncolytic virus therapies, demonstrating the continued evolution of cancer treatment.

This approval also underscores the critical importance of specialized clinical expertise within the regulatory review process. The reported positive advisory committee vote, which acknowledged the unmet need and corrected agency errors, highlights how expert input can be instrumental in navigating complex data and ensuring that promising innovations reach patients faster. Strategically, this not only provides a distinct therapeutic option in a crowded market but also validates the broader oncolytic virus platform, potentially paving the way for future developments across other challenging indications.

However, the path forward is not without considerations. As an accelerated approval, the long-term efficacy and overall survival benefits of RP1 will require robust confirmation through ongoing studies. The competitive landscape of advanced melanoma, with its array of established and emerging combination therapies, will necessitate clear differentiation and value proposition for RP1. Furthermore, while oncolytic viruses have shown promise, their integration into combination regimens will demand careful evaluation of safety and efficacy, given that some multi-drug combinations in melanoma have been associated with significant adverse events. Ultimately, this approval represents a step forward, emphasizing the continuous need for innovation and rigorous evaluation to improve patient outcomes in advanced melanoma.